Wanbury Limited’s subsidiary, Wanbury Skin Health, has launched the 'berrysoft' baby care range, marking the company’s formal entry into the paediatric dermatology segment. By utilizing its existing network of paediatricians used for its cold and cough medicines, Wanbury aims to cross-sell these new skincare and hygiene products. The company has already secured GST registrations and drug licenses across multiple states to facilitate a nationwide rollout.
Wanbury Expands into Paediatric Skincare With berrysoft Launch
- Product Launch: berrysoft baby care range
- Strategic Focus: Paediatric dermatology segment
Reader Takeaway: Wanbury leverages its established paediatrician network to cross-sell new skincare products, diversifying its healthcare portfolio beyond cold and cough medicine.
What just happened
Wanbury Skin Health Limited, a subsidiary of Wanbury Limited, has officially launched its 'berrysoft' range of baby skincare and hygiene products. This launch marks the company’s strategic entry into the paediatric dermatology market. Initial offerings include a gentle bathing bar, body wash, foam shampoo, and syndet handwash. Additional products, such as diaper rash creams and moisturising lotions, are currently in the product pipeline.
Why this matters
This expansion allows Wanbury to diversify its revenue streams beyond its core cold and cough medication business. By tapping into its existing commercial infrastructure and professional relationships with paediatricians, the company expects to optimize its distribution and marketing efforts. The company is systematically building its operational footprint, with GST registrations now active in five states—including Maharashtra, Delhi, and Karnataka—and CFA licenses already secured in Mumbai, Jaipur, Patna, and Ambala.
What changes now
Wanbury is shifting its focus toward deeper engagement with the medical community. While the current launch targets paediatricians, management has indicated plans to extend these efforts to dermatologists to support future growth in the broader dermatology segment. The company is continuing to scale its backend, with additional state registrations and drug licenses currently in the pipeline to support wider product availability.
What to track next
Investors should monitor the speed of the national rollout and the market adoption rates of the berrysoft range. Future quarterly filings may provide insights into the contribution of this new segment to the company’s overall healthcare portfolio revenue.